John Davidson Elected to Allergan Board of Directors

DUBLIN, May 3, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that John Davidson has been elected to its Board of Directors. Mr. Davidson and the other directors standing for re-election to Allergan’s Board were elected at Allergan’s Annual General Meeting of Shareholders on May 2, 2018. With the addition of Mr. Davidson, and the previously announced retirement of directors James Bloem and Ronald Taylor, the Allergan Board now has 12 members.

“John Davidson’s vast experience with complex accounting and financial issues, his experience serving of Boards of self-regulatory organizations and his more than 30 years of leadership across multiple industries, make him a valuable asset to our Board of Directors,” said Brent L. Saunders, Chairman and Chief Executive Officer at Allergan. “John has a deep understanding of how global teams are managed and a strong track record of implementing governance and control process improvements, two skills that our Board values.”

Mr. Davidson retired from Tyco International in 2012, having served as senior vice president, controller and chief accounting officer. Mr. Davidson was responsible for overseeing financial reporting, internal controls, and accounting policies and processes. He joined Tyco in 2004, working as part of the new senior leadership team in establishing financial integrity, operational excellence and strong ethical practices across Tyco global operations.

Since 2012, Mr. Davidson has served on the board of governors of the Financial Industry Regulatory Authority (FINRA) which regulates and oversees the US financial industry in the interest of investor protection and market integrity.

“I’m honored to join Allergan’s Board of Directors and I look forward to supporting its commitment to drive value for shareholders,” said Davidson. “Allergan has a strong business and an impressive portfolio of products delivering innovation for patients around the world. It’s an exciting time to join Allergan and I look forward to contributing to the company’s future success.”

Prior to joining Tyco International, Mr. Davidson served as vice president, audit, risk and compliance for Dell Inc. During his six-year career at Dell he also served in other senior capacities, including chief compliance officer and vice president and corporate controller. In addition, Mr. Davidson spent 16 years with Eastman Kodak Company where he led the company’s internal audit function and previously served in a variety of accounting and financial leadership roles. He began his career with Arthur Andersen & Co. From 2011 to 2015 he served as a member of the board of trustees of the Financial Accounting Foundation which oversees the FASB and GASB in accounting standards setting. Mr. Davidson serves as a trustee of University of Rochester, where he earned an MBA in Finance. He received a Bachelor of Science in Accounting from St. John Fisher College. Mr. Davidson has been inducted into the Financial Executives International (FEI) Hall of Fame.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan’s success is powered by our global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS^®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan’s Quarterly Report on Form 10-Q for the period ended March 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS: Allergan:
Investors:
Daphne Karydas
(862) 261-8006

Karina Calzadilla
(862) 261-7328

Media:
Amy Rose
(862) 289-3072

Lisa Brown
(862) 261-7320